Dcld case
Asking for Preferences
Asking for Preferences
Reading File
Finding Sources
Searching PubMed
"chronic liver disease" AND cirrhosis
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Diffuse Chronic Liver Disease (DCLD) - Full Clinical Case Discussion
Definition & Concept
DCLD refers to any chronic, progressive, diffuse disease of the liver parenchyma that leads to hepatocellular damage, fibrosis, and - if unchecked - cirrhosis. The end-point is a liver in which normal architecture is replaced by fibrous septa subdividing the parenchyma into regenerative hepatocellular nodules. It is the third leading cause of premature death in the UK, deaths have risen 400% since 1970, and 75% of patients still present with late-stage disease.
- Bailey and Love's Short Practice of Surgery 28e, p. 1216
Sample Case Vignette
A 52-year-old male, chronic alcoholic, presents with abdominal distension, jaundice, and confusion for 3 weeks. On examination: icteric, spider naevi on chest, palmar erythema, leukonychia, bilateral parotid enlargement, gynecomastia, testicular atrophy, flapping tremor (asterixis) on outstretched hands, massive ascites with shifting dullness, splenomegaly. No pedal oedema. History of two prior haematemesis episodes.
Etiology
The major causes of DCLD leading to cirrhosis:
| Category | Specific Causes |
|---|---|
| Toxic/Metabolic | Alcohol (most common in Western countries), NAFLD/MASLD, NASH |
| Viral | Hepatitis B, Hepatitis C, Hepatitis D (co-infection with HBV) |
| Autoimmune | Autoimmune hepatitis, Primary Biliary Cirrhosis (PBC), Primary Sclerosing Cholangitis (PSC) |
| Cholestatic | Secondary biliary cirrhosis (chronic biliary obstruction) |
| Vascular | Budd-Chiari syndrome, cardiac cirrhosis (right heart failure), sinusoidal obstruction syndrome |
| Genetic/Metabolic | Haemochromatosis, Wilson's disease, Alpha-1 antitrypsin deficiency |
| Cryptogenic | ~10-15% after full workup |
- Sleisenger & Fordtran's GI and Liver Disease, p. 1413
- Schwartz's Principles of Surgery 11e, p. 1389
Pathophysiology
Chronic hepatic injury (from any cause) triggers sustained wound healing:
- Hepatocyte injury - necrosis / apoptosis
- Activation of hepatic stellate cells (HSCs) - the key fibrogenic cells; transform into myofibroblasts
- TGF-beta driven collagen deposition - fibrous septa form
- Distortion of vascular architecture - intrahepatic vascular resistance rises → portal hypertension
- Regenerative nodules - compensatory hepatocyte proliferation in an abnormal scaffold
- Failure of synthetic, metabolic, and detoxifying functions → clinical decompensation
Cirrhosis is not a static end-state; fibrosis can regress with removal of the causative agent (especially in viral and alcoholic liver disease).
Clinical Features
General
- Lethargy, weakness, weight loss (often the earliest features)
- Fever (related to cytokine release or bacterial translocation)
- Jaundice (conjugation and excretion of bilirubin both fail in advanced disease)
Cutaneous Signs
- Spider naevi - cutaneous vascular abnormalities that blanch on pressure; >5 are significant; upper half of body (SVC territory)
- Palmar erythema - mottled erythema over thenar/hypothenar eminences
- Leukonychia (white nails) / Terry's nails
- Dupuytren's contracture (especially alcoholic)
- Caput medusae (dilated periumbilical veins due to portal hypertension)
- Scratch marks (cholestatic pruritus in PBC/PSC)
Endocrine / Haematological
- Hypogonadism, loss of body hair, gynaecomastia, testicular atrophy (excess oestrogen, decreased testosterone metabolism)
- Parotid enlargement, Dupuytren's - especially in alcohol
- Anaemia (multifactorial - haemorrhage, hypersplenism, B12/folate deficiency, haemolysis)
- Thrombocytopenia (hypersplenism + decreased thrombopoietin synthesis)
- Coagulopathy - bruising, prolonged PT (decreased clotting factor synthesis)
Cardiovascular
- Hyperdynamic circulation: high cardiac output, large bounding pulse, low BP, flushed warm extremities (due to vasodilation, especially nitric oxide-mediated splanchnic vasodilation)
Neurological - Hepatic Encephalopathy (HE)
- Memory impairment, confusion, personality changes, altered sleep pattern, slow/slurred speech
- Asterixis (flapping tremor) - most useful clinical sign; test with outstretched arms and hyperextended wrists
Grades of HE:
| Grade | Features |
|---|---|
| I | Inverted sleep pattern, forgetfulness, irritability, apraxia |
| II | Lethargy, disorientation in time/place, personality change, ataxia |
| III | Somnolence, responds to verbal stimuli, place disorientation, asterixis, hyperreflexia |
| IV | Coma |
- Bailey and Love's 28e, p. 1217
Portal Hypertension (PHT)
Normal portal pressure = 5-10 mmHg. PHT = >12 mmHg (clinically significant).
Consequences:
- Ascites - the most common late feature; shifting dullness/fluid thrill on exam
- Oesophageal/gastric varices - risk of life-threatening haematemesis
- Splenomegaly - leads to hypersplenism (pancytopenia)
- Portosystemic collaterals: caput medusae, haemorrhoids, retroperitoneal varices
The portal vein tributaries communicate with systemic veins at:
-
Gastroesophageal junction (→ varices)
-
Anal canal (→ haemorrhoids)
-
Falciform ligament (→ caput medusae)
-
Retroperitoneum
-
Schwartz's Principles of Surgery 11e, p. 1390
Investigations
Liver Function Tests
| Test | What It Tells You |
|---|---|
| Bilirubin (raised) | Impaired conjugation/excretion |
| Albumin (low) | Reduced synthetic function |
| PT/INR (prolonged) | Reduced clotting factor synthesis |
| ALT/AST (raised, or low in burnt-out cirrhosis) | Hepatocellular injury |
| ALP/GGT (raised) | Cholestasis component |
Haematology
- FBC: anaemia, thrombocytopenia, leucopenia (hypersplenism)
- Coagulation screen: prolonged PT, raised INR
Imaging
- Ultrasound abdomen - first-line: liver size, echogenicity, surface nodularity, ascites, portal vein diameter (>13 mm suggests PHT), splenomegaly, Doppler for portal flow
- CT/MRI abdomen - better characterization; identifies varices, HCC nodules, hepatic vein patency
- Fibroscan (transient elastography) - non-invasive staging of fibrosis (2025 AASLD guideline-supported)
- Upper GI endoscopy - mandatory to screen for varices
Special Tests (Etiology)
- HBsAg, Anti-HCV, Anti-HBc
- ANA, ASMA (autoimmune hepatitis), AMA (PBC)
- Serum ceruloplasmin, 24h urine copper, slit-lamp exam for KF rings (Wilson's)
- Serum ferritin + transferrin saturation, HFE gene (haemochromatosis)
- Alpha-1 antitrypsin level + phenotype
Liver Biopsy
- Gold standard for diagnosis, staging fibrosis (METAVIR/Ishak score), and etiology
- Percutaneous vs. transjugular (if coagulopathy/ascites)
Severity Scoring
Child-Turcotte-Pugh (CTP) Score
| Variable | 1 Point | 2 Points | 3 Points |
|---|---|---|---|
| Bilirubin (µmol/L) | <34 | 34-50 | >50 |
| Albumin (g/L) | >35 | 25-35 | <25 |
| Ascites | None | Easily controlled | Poorly controlled |
| Encephalopathy | None | Grade I-II | Grade III-IV |
| INR | <1.7 | 1.7-2.2 | >2.2 |
- CTP-A (5-6 pts): Compensated; surgical mortality ~10%
- CTP-B (7-9 pts): Moderate decompensation; surgical mortality ~30%
- CTP-C (10-15 pts): Severe decompensation; surgical mortality 75-80%
MELD Score
MELD = 9.57 × ln(creatinine) + 3.78 × ln(bilirubin) + 11.2 × ln(INR) + 6.43
-
Used for liver transplant prioritization (USA since 2002)
-
MELD <10 → can safely undergo elective surgery
-
MELD 10-15 → surgery with caution
-
MELD >15 → avoid elective surgery
-
Bailey and Love's 28e, p. 1217; Schwartz's 11e, p. 1390
Complications Summary
| Complication | Key Points |
|---|---|
| Ascites | Na restriction, diuretics (spironolactone ± furosemide), paracentesis for tense ascites + albumin replacement, TIPSS for refractory ascites |
| Spontaneous Bacterial Peritonitis (SBP) | PMN >250/mm³ in ascitic fluid; treat with cefotaxime + albumin; prophylaxis with norfloxacin/ciprofloxacin |
| Variceal bleeding | Acute: terlipressin/octreotide + band ligation + antibiotics; Secondary prophylaxis: propranolol + band ligation; TIPSS if refractory |
| Hepatic Encephalopathy | Lactulose (NH3 trapping), rifaximin (gut flora), identify/treat precipitants (constipation, infection, bleeding, drugs, hyponatraemia) |
| Hepatorenal Syndrome (HRS) | Type 1 (acute, rapidly progressive), Type 2 (chronic); Rx: terlipressin + albumin; liver transplant is definitive |
| Coagulopathy | Vitamin K, FFP if bleeding; avoid over-correcting - these patients have balanced coagulation |
| Hepatocellular Carcinoma (HCC) | 6-monthly surveillance USS ± AFP in all cirrhotics |
| Sarcopenia/Malnutrition | High-calorie, high-protein diet (1.2-1.5 g/kg/day protein); BCAA supplementation |
Surgical Risk in DCLD
All surgery in DCLD carries elevated risk:
- Hepatotoxic anaesthetic agents exacerbate function
- Coagulopathy → increased intraoperative bleeding
- Reduced drug metabolism → altered pharmacokinetics
- Impaired wound healing
- Higher infection risk (innate immune dysfunction)
CTP-A: 10% operative mortality
CTP-B: 30% operative mortality
CTP-C: 75-80% operative mortality
Avoid elective surgery in CTP-C / MELD >15.
Rare but Important Chronic Liver Conditions
| Condition | Presentation | Notes |
|---|---|---|
| Primary Sclerosing Cholangitis (PSC) | Abnormal LFTs, pruritus, jaundice | Associated with UC; beaded appearance on MRCP; predisposes to cholangiocarcinoma |
| Primary Biliary Cirrhosis (PBC) | Malaise, lethargy, pruritus | Middle-aged women; AMA positive; ursodeoxycholic acid treatment |
| Budd-Chiari Syndrome | Ascites, pain, abdominal distension | Hepatic vein thrombosis; anticoagulation/TIPSS/OLT |
| Haemochromatosis | Diabetes, cirrhosis, skin pigmentation, hypogonadism | HFE C282Y mutation; venesection |
| Wilson's Disease | Young patient, hepatic + neuropsychiatric features | KF rings; low ceruloplasmin; D-penicillamine/trientine |
- Bailey and Love's 28e, p. 1219
Definitive Treatment: Liver Transplantation (OLT)
Indications include:
- MELD >15 / CTP-C
- Refractory ascites, recurrent variceal bleeding, intractable HE
- HCC within Milan criteria (single lesion <5 cm, or up to 3 lesions all <3 cm, no vascular invasion)
- Acute-on-chronic liver failure (ACLF)
5-year survival post-transplant: ~70-80% for most indications.
Recent Evidence (2024-2025)
- AASLD 2025 guideline supports imaging-based non-invasive liver disease assessment (vibration-controlled transient elastography, MR elastography) for staging fibrosis in CLD, reducing need for biopsy - Hepatology 2025 [PMID: 38489521]
- A 2024 systematic review confirmed that Acute-on-Chronic Liver Failure (ACLF) definitions vary globally but the CLIF-C ACLF score robustly predicts 28-day mortality [PMID: 38750869]
- Novel agents for MASLD/NASH (GLP-1 agonists, THR-beta agonists like resmetirom) show significant benefit in reversing steatohepatitis and fibrosis [PMID: 39357599]
Quick Reference: Precipitants of Acute Decompensation in DCLD
- Infection (especially SBP)
- GI bleeding (variceal or non-variceal)
- Alcohol binge
- Constipation
- Electrolyte disturbance (hyponatraemia, hypokalaemia)
- Drugs (opioids, benzodiazepines, diuretics)
- Hepatocellular carcinoma development
- Portal vein thrombosis
Key takeaway: DCLD / cirrhosis is a dynamic process - early identification, treatment of the underlying cause, and surveillance for complications (varices, HCC) are the pillars of management. Liver transplantation remains the only definitive cure for end-stage disease.
This is a shared conversation. Sign in to Orris to start your own chat.